Haier Biomedical Highlights Industry Traits of Vast Market, Niche Segments, Diverse Products and Applications

Qingdao Haier Biomedical Co., Ltd. stated during an investor inquiry that the industry it operates in is characterized by a large total market size, numerous niche segments, a wide array of products, and diverse applications. From a fundamental technology perspective, the differences between various niche segments are significant. Consequently, the company views expansion through mergers and acquisitions to rapidly enter new segments, followed by post-investment integration to gradually enhance overall competitiveness, and ultimately building a platform-based enterprise covering multiple scenarios as crucial for its medium to long-term sustainable development. Since its initial public offering, the company has completed six acquisitions. The focus of these acquisitions has been to provide existing customers with more products and continuous services within the same usage scenarios. This strategy has not only strengthened the company's portfolio of low-temperature storage products but also extended its hospital scenario solutions into smart medication management, enabled entry into the blood technology segment, and progressively built out integrated laboratory hardware, software, and service solutions. In the domestic market, repeat customers account for 40% of its user base. This not only fulfills user demand through one-stop solutions but also increases the value per customer. The value per customer for scenario-based solution businesses can reach the million-yuan level. With the proposal for the 15th Five-Year Plan for the first time listing biomanufacturing as one of the six key future industry tracks, the sector is facing a historic development opportunity. Currently, the company is upgrading its M&A strategy towards platform-level acquisitions. It aims to more actively seize opportunities presented by the industry cycle, accelerate布局 in high-potential segments centered on core scenarios from molecular discovery to commercial production, focus on serving life science customers, and increase the proportion of recurring business revenue.